首页 | 本学科首页   官方微博 | 高级检索  
     

健脾解毒方对人结肠癌多药耐药细胞的逆转作用
引用本文:隋华,靳宝辉,殷佩浩,范忠泽,李琦. 健脾解毒方对人结肠癌多药耐药细胞的逆转作用[J]. 中国实验方剂学杂志, 2012, 18(9): 196-200
作者姓名:隋华  靳宝辉  殷佩浩  范忠泽  李琦
作者单位:上海中医药大学附属普陀医院,上海中医药大学中西医结合肿瘤介入研究所,上海 200062
基金项目:上海市自然科学基金项目(10ZR1427400;10140902600);上海市卫生系统优秀学科带头人项目(XBR2011061);上海市教育委员会创新项目(09YZ132);上海市重点学科项目(S30302)
摘    要:目的:探讨健脾解毒方对人结肠癌多药耐药细胞HCT8/V的逆转作用及其可能机制.方法:人结肠癌HCT8/V多药耐药细胞常规培养,5%健脾解毒方药物血清作用48 h后,MTT法检测HCT8/V细胞对化疗药敏感性的影响,高效液相色谱法( HPLC)检测耐药细胞内长春新碱(VCR)药物浓度,流式细胞仪分析健脾解毒方对5-氟尿嘧啶(5-Fu)诱导的HCT8/V细胞凋亡和细胞周期的影响.结果:健脾解毒方能增加HCT8/V细胞对VCR、顺铂(DDP)、5-Fu、吡柔比星(THP)4种化疗药物的敏感性,4种化疗药的IC50分别从( 191.08±18.18 )mg·L-1下降到(90.13±6.33 )mg·L-1;(290.79±28.38) mg·L-1下降到(22.16±1.82) mg·L-1;(23.12±1.99) mg·L-1下降到(9.88±0.86 )mg·L-1;(26.40±2.92) mg·L-1下降到(19.41±1.48) mg·L-1;健脾解毒方药物血清作用HCT8/V细胞48 h后细胞内VCR浓度明显增高(P<0.01),且呈剂量依赖性.健脾解毒方能提高5-Fu诱导的HCT8/V细胞的凋亡率,使细胞阻滞于G1期.结论:健脾解毒方通过增加结肠癌多药耐药细胞内化疗药物浓度,抑制细胞增殖,诱导其凋亡,逆转HCT8/V细胞株的多药耐药性.

关 键 词:结肠癌  多药耐药  凋亡  健脾解毒方
收稿时间:2011-10-24

Reversal Effect of Jianpi Jiedu Formula on Multidrug Resistance in Human Colon Carcinoma Cells
SUI Hu,JIN Bao-hui,YIN Pei-hao,FAN Zhong-ze and LI Qi. Reversal Effect of Jianpi Jiedu Formula on Multidrug Resistance in Human Colon Carcinoma Cells[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2012, 18(9): 196-200
Authors:SUI Hu  JIN Bao-hui  YIN Pei-hao  FAN Zhong-ze  LI Qi
Affiliation:Putuo Hospital, Shanghai University of Traditional Chinese Medicine(TCM);Interventional Cancer Institute of Chinese Integrative Medicine, Shanghai University of TCM, Shanghai 200062, China;Putuo Hospital, Shanghai University of Traditional Chinese Medicine(TCM);Interventional Cancer Institute of Chinese Integrative Medicine, Shanghai University of TCM, Shanghai 200062, China;Putuo Hospital, Shanghai University of Traditional Chinese Medicine(TCM);Interventional Cancer Institute of Chinese Integrative Medicine, Shanghai University of TCM, Shanghai 200062, China;Putuo Hospital, Shanghai University of Traditional Chinese Medicine(TCM);Interventional Cancer Institute of Chinese Integrative Medicine, Shanghai University of TCM, Shanghai 200062, China;Putuo Hospital, Shanghai University of Traditional Chinese Medicine(TCM);Interventional Cancer Institute of Chinese Integrative Medicine, Shanghai University of TCM, Shanghai 200062, China
Abstract:Objective: To investigate the mechanisms and reversal effects of Jianpi Jiedu formula on human colon carcinoma multidrug resistance (MDR) in HCT8/V cells. Method: Human colon carcinoma MDR cells were cultured conventionally. The concentration of Jianpi Jiedu formula (5%) combined with chemotherapy drugs and the reversal effect of multidrug resistance (MDR) in HCT8/V cells was evaluated by the MTT assay. The variation of intracellular concentration of vincristine(VCR) in HCT8/V cells was evaluated by the HPLC, and the effects of Jianpi Jiedu formula on 5-Fu induced apoptosis and cell cycle were evaluated by flow cytometry (FCM). Result: Jianpi Jiedu formula could increase the sensitivity of HCT8/V cells to VCR,DDP,5-Fu,THP. The IC50 value of VCR decreased from (191.08±18.18) mg·L-1 to (90.13±6.33) mg·L-1, DDP was from (290.79±28.38) mg·L-1 to (22.16±1.82) mg·L-1, 5-Fu was from (23.12±1.99) mg·L-1 to (9.88±0.86) mg·L-1, and THP was from (26.40±2.92) mg·L-1 to (19.41±1.48) mg·L-1. HPLC results showed that Jianpi Jiedu formula increased the concentration of drugs in HCT8/V cells in a dose-dependent manner after treatment for 48 h. Flow cytometry assay result verified that the inhibited effects of Jianpi Jiedu formula combined with 5-Fu on the proliferation of HCT8/V cells was closely related to the arrest in G1 phase and increasing of apoptosis. Conclusion: Jianpi Jiedu formula can reverse MDR in HCT8/V cell, which possibly through inhibiting cell proliferation, inducing cell-apoptosis, ultimately affect the concentration of drugs inside the cells.
Keywords:colon carcinoma  multidrug-resistance  apoptosis  Jianpi Jiedu formula
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号